<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311608</url>
  </required_header>
  <id_info>
    <org_study_id>CSY-LB2-2014</org_study_id>
    <nct_id>NCT02311608</nct_id>
  </id_info>
  <brief_title>Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails</brief_title>
  <acronym>CER:T</acronym>
  <official_title>Comparative Effectiveness Research: Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails to Treat the Patients With Acute Variceal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and access the Effects and safety of terlipressin or high dose
      somatostatin/octreotide when usual dose somatostatin/octreotide fail to achieve hemostasis in
      patients with acute variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis information of the patients with acute variceal bleeding will be collected,
      including hemostasis rate, early rebleeding rate, mortality, complications, severity adverse
      events, economic burdens and quality of life, when terlipressin or high dose
      somatostatin/octreotide is used as salvation to patients fail to achieve initial
      hemostasis.The results may help gastroenterologists to make decisions when administering
      vasoactive medicines to those suffered from acute variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Change of Rebleeding Rate</measure>
    <time_frame>1month, 3months, 6 months, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Economic Cost</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of Quality of Life</measure>
    <time_frame>1month, 3months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of Survival Rate</measure>
    <time_frame>1month, 3months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of Complication Rate</measure>
    <time_frame>1month, 3months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of Drug Adverse Reaction Rate</measure>
    <time_frame>1month, 3months, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1320</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Esophageal and Gastric Varices</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>High Dose Somatostatin/Octreotide</arm_group_label>
    <description>continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terlipressin as salvage</arm_group_label>
    <description>an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terlipr+usual dose somato/Octreo</arm_group_label>
    <description>an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control:Usual Dose Somato/Octreo</arm_group_label>
    <description>Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Initial Terlipressin</arm_group_label>
    <description>Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>administered as a first-line medicine or as salvage</description>
    <arm_group_label>Terlipressin as salvage</arm_group_label>
    <arm_group_label>Terlipr+usual dose somato/Octreo</arm_group_label>
    <arm_group_label>Control: Initial Terlipressin</arm_group_label>
    <other_name>Hanwei</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Dose Somatostatin/Octreotide</intervention_name>
    <description>administered as a first-line medicine or as salvage</description>
    <arm_group_label>High Dose Somatostatin/Octreotide</arm_group_label>
    <arm_group_label>Terlipressin as salvage</arm_group_label>
    <arm_group_label>Terlipr+usual dose somato/Octreo</arm_group_label>
    <arm_group_label>Control:Usual Dose Somato/Octreo</arm_group_label>
    <other_name>Yisuo/Shanning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Somatostatin/Octreotide</intervention_name>
    <description>administered as salvage</description>
    <arm_group_label>High Dose Somatostatin/Octreotide</arm_group_label>
    <arm_group_label>Terlipr+usual dose somato/Octreo</arm_group_label>
    <other_name>Yisuo/Shanning</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cirrohsis patients with acute variceal bleeding
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis patients admitted to Emergency Department because of acute variceal bleeding

        Exclusion Criteria:

          -  No signs of variceal bleeding are found by endoscopy or portal hypertensive
             gastropathy is responsible for the bleeding

          -  Patients undergo endoscopy after 72h from the beginning of acute variceal bleeding

          -  Patients with hepatorenal syndrome

          -  Patients with ischemia organic cardiopathy (including myocardial infarction or
             unstable angina pectoris) or myocardial ischemia indicated by ECG in the past 6 months

          -  Patients allergic to/with contraindications of vasoactive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao Chen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiyao Chen, Professor</last_name>
    <phone>86-13701761310</phone>
    <email>chen.shiyao@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Li, Doctor</last_name>
      <phone>86-18021057696</phone>
      <email>07301010228@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Azam Z, Hamid S, Jafri W, Salih M, Abbas Z, Abid S, Shah H. Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial. J Hepatol. 2012 Apr;56(4):819-24. doi: 10.1016/j.jhep.2011.11.019. Epub 2011 Dec 16.</citation>
    <PMID>22178268</PMID>
  </reference>
  <reference>
    <citation>Kalambokis G, Economou M, Paraskevi K, Konstantinos P, Pappas C, Katsaraki A, Tsianos EV. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. J Gastroenterol Hepatol. 2005 Jul;20(7):1075-81.</citation>
    <PMID>15955217</PMID>
  </reference>
  <reference>
    <citation>Romero G, Kravetz D, Argonz J, Bildozola M, Suarez A, Terg R. Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients. J Hepatol. 2000 Mar;32(3):419-25.</citation>
    <PMID>10735611</PMID>
  </reference>
  <reference>
    <citation>Lo GH, Perng DS, Chang CY, Tai CM, Wang HM, Lin HC. Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding. J Gastroenterol Hepatol. 2013 Apr;28(4):684-9. doi: 10.1111/jgh.12107.</citation>
    <PMID>23278466</PMID>
  </reference>
  <reference>
    <citation>Solà E, Lens S, Guevara M, Martín-Llahí M, Fagundes C, Pereira G, Pavesi M, Fernández J, González-Abraldes J, Escorsell A, Mas A, Bosch J, Arroyo V, Ginès P. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology. 2010 Nov;52(5):1783-90. doi: 10.1002/hep.23893.</citation>
    <PMID>20931555</PMID>
  </reference>
  <reference>
    <citation>Abid S, Jafri W, Hamid S, Salih M, Azam Z, Mumtaz K, Shah HA, Abbas Z. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol. 2009 Mar;104(3):617-23. doi: 10.1038/ajg.2008.147. Epub 2009 Feb 17.</citation>
    <PMID>19223890</PMID>
  </reference>
  <reference>
    <citation>Lo GH, Chen WC, Wang HM, Lin CK, Chan HH, Tsai WL, Cheng LC, Yu HC, Tsay FW. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut. 2009 Sep;58(9):1275-80. doi: 10.1136/gut.2008.165910. Epub 2009 Apr 21.</citation>
    <PMID>19386609</PMID>
  </reference>
  <reference>
    <citation>Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006 Sep 15;24(6):935-44. Review.</citation>
    <PMID>16948805</PMID>
  </reference>
  <reference>
    <citation>D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology. 2003 May;124(5):1277-91.</citation>
    <PMID>12730868</PMID>
  </reference>
  <reference>
    <citation>Escorsell A, Ruiz del Arbol L, Planas R, Albillos A, Bañares R, Calès P, Pateron D, Bernard B, Vinel JP, Bosch J. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology. 2000 Sep;32(3):471-6.</citation>
    <PMID>10960437</PMID>
  </reference>
  <results_reference>
    <citation>Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ, Lee SS. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol. 2005 Mar;100(3):631-5.</citation>
    <PMID>15743362</PMID>
  </results_reference>
  <results_reference>
    <citation>Villanueva C, Planella M, Aracil C, López-Balaguer JM, González B, Miñana J, Balanzó J. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol. 2005 Mar;100(3):624-30.</citation>
    <PMID>15743361</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Director of department fo Gastroenterology, Zhongshan Hospital</investigator_title>
  </responsible_party>
  <keyword>acute variceal hemorrhage</keyword>
  <keyword>terlipressin</keyword>
  <keyword>somatostatin</keyword>
  <keyword>octreotide</keyword>
  <keyword>comparative effectiveness research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

